Trial
NCT04373083
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
Sanofi
Condition
Hodgkin Lymphoma
Intervention
Cemiplimab
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-15